Literature DB >> 27758824

CK2 inhibitor CX-4945 destabilizes NOTCH1 and synergizes with JQ1 against human T-acute lymphoblastic leukemic cells.

Haiwei Lian1,2,3, Dun Li2,4, Yun Zhou2,5, Esther Landesman-Bollag4, Guanglan Zhang6, Nicole M Anderson2, Kevin Charles Tang2, Justine E Roderick7, Michelle A Kelliher7, David C Seldin4, Hui Fu8, Hui Feng9,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27758824      PMCID： PMC5210253          DOI： 10.3324/haematol.2016.154013

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Proteasome inhibitor MG132-induced apoptosis via ER stress-mediated apoptotic pathway and its potentiation by protein tyrosine kinase p56lck in human Jurkat T cells.

Authors:  Hae Sun Park; Do Youn Jun; Cho Rong Han; Hyun Ju Woo; Young Ho Kim
Journal:  Biochem Pharmacol       Date:  2011-07-23       Impact factor: 5.858

2.  Hierarchical phosphorylation within the ankyrin repeat domain defines a phosphoregulatory loop that regulates Notch transcriptional activity.

Authors:  Prathibha Ranganathan; Rodrigo Vasquez-Del Carpio; Fred M Kaplan; Hong Wang; Ashu Gupta; Jeffrey D VanWye; Anthony J Capobianco
Journal:  J Biol Chem       Date:  2011-06-17       Impact factor: 5.157

3.  ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth.

Authors:  Lori S Hart; John T Cunningham; Tatini Datta; Souvik Dey; Feven Tameire; Stacey L Lehman; Bo Qiu; Haiyan Zhang; George Cerniglia; Meixia Bi; Yan Li; Yan Gao; Huayi Liu; Changhong Li; Amit Maity; Andrei Thomas-Tikhonenko; Alexander E Perl; Albert Koong; Serge Y Fuchs; J Alan Diehl; Ian G Mills; Davide Ruggero; Constantinos Koumenis
Journal:  J Clin Invest       Date:  2012-11-12       Impact factor: 14.808

4.  c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells.

Authors:  Justine E Roderick; Jessica Tesell; Leonard D Shultz; Michael A Brehm; Dale L Greiner; Marian H Harris; Lewis B Silverman; Stephen E Sallan; Alejandro Gutierrez; A Thomas Look; Jun Qi; James E Bradner; Michelle A Kelliher
Journal:  Blood       Date:  2014-01-06       Impact factor: 22.113

5.  Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling.

Authors:  F Buontempo; E Orsini; L R Martins; I Antunes; A Lonetti; F Chiarini; G Tabellini; C Evangelisti; C Evangelisti; F Melchionda; A Pession; A Bertaina; F Locatelli; J A McCubrey; A Cappellini; J T Barata; A M Martelli
Journal:  Leukemia       Date:  2013-11-20       Impact factor: 11.528

Review 6.  Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas.

Authors:  Teresa Palomero; Adolfo Ferrando
Journal:  Clin Cancer Res       Date:  2008-09-01       Impact factor: 12.531

7.  Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia.

Authors:  Pieter Van Vlierberghe; Alberto Ambesi-Impiombato; Kim De Keersmaecker; Michael Hadler; Elisabeth Paietta; Martin S Tallman; Jacob M Rowe; Carles Forne; Montserrat Rue; Adolfo A Ferrando
Journal:  Blood       Date:  2013-05-17       Impact factor: 22.113

8.  PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability.

Authors:  Ana Silva; J Andrés Yunes; Bruno A Cardoso; Leila R Martins; Patrícia Y Jotta; Miguel Abecasis; Alexandre E Nowill; Nick R Leslie; Angelo A Cardoso; Joao T Barata
Journal:  J Clin Invest       Date:  2008-10-01       Impact factor: 14.808

9.  FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.

Authors:  Jennifer O'Neil; Jonathan Grim; Peter Strack; Sudhir Rao; Deanne Tibbitts; Christopher Winter; James Hardwick; Markus Welcker; Jules P Meijerink; Rob Pieters; Giulio Draetta; Rosalie Sears; Bruce E Clurman; A Thomas Look
Journal:  J Exp Med       Date:  2007-07-23       Impact factor: 14.307

10.  AIP4/Itch regulates Notch receptor degradation in the absence of ligand.

Authors:  Patricia Chastagner; Alain Israël; Christel Brou
Journal:  PLoS One       Date:  2008-07-16       Impact factor: 3.240
View more
  8 in total

Review 1.  CK2 and the Hallmarks of Cancer.

Authors:  May-Britt Firnau; Angela Brieger
Journal:  Biomedicines       Date:  2022-08-16

2.  Excess Translation of Epigenetic Regulators Contributes to Fragile X Syndrome and Is Alleviated by Brd4 Inhibition.

Authors:  Erica Korb; Margaret Herre; Ilana Zucker-Scharff; Jodi Gresack; C David Allis; Robert B Darnell
Journal:  Cell       Date:  2017-08-17       Impact factor: 41.582

Review 3.  Therapeutic targeting of CK2 in acute and chronic leukemias.

Authors:  F Buontempo; J A McCubrey; E Orsini; M Ruzzene; A Cappellini; A Lonetti; C Evangelisti; F Chiarini; C Evangelisti; J T Barata; A M Martelli
Journal:  Leukemia       Date:  2017-09-27       Impact factor: 11.528

Review 4.  Super-enhancers: critical roles and therapeutic targets in hematologic malignancies.

Authors:  Yunlu Jia; Wee-Joo Chng; Jianbiao Zhou
Journal:  J Hematol Oncol       Date:  2019-07-16       Impact factor: 17.388

5.  Transcriptional Regulation of PIK3CD and PIKFYVE in T-Cell Acute Lymphoblastic Leukemia by IKAROS and Protein Kinase CK2.

Authors:  Elanora Dovat; Chunhua Song; Tommy Hu; Mohammad Atiqur Rahman; Pavan Kumar Dhanyamraju; Morgann Klink; Daniel Bogush; Mario Soliman; Shriya Kane; Mary McGrath; Yali Ding; Dhimant Desai; Arati Sharma; Chandrika Gowda
Journal:  Int J Mol Sci       Date:  2021-01-15       Impact factor: 5.923

Review 6.  Post-Translational Modifications of BRD4: Therapeutic Targets for Tumor.

Authors:  Na Liu; Rui Ling; Xiang Tang; Yunpeng Yu; Yuepeng Zhou; Deyu Chen
Journal:  Front Oncol       Date:  2022-03-21       Impact factor: 6.244

7.  CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism.

Authors:  Jomnarong Lertsuwan; Kornkamon Lertsuwan; Anyaporn Sawasdichai; Nathapol Tasnawijitwong; Ka Ying Lee; Philip Kitchen; Simon Afford; Kevin Gaston; Padma-Sheela Jayaraman; Jutamaad Satayavivad
Journal:  Cancers (Basel)       Date:  2018-08-23       Impact factor: 6.639

Review 8.  Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy - potential clinical relevance.

Authors:  Claudio D'Amore; Christian Borgo; Stefania Sarno; Mauro Salvi
Journal:  Cell Oncol (Dordr)       Date:  2020-10-14       Impact factor: 6.730
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.